Viriom
Viriom is a pharmaceutical company developing new treatments for viral diseases and solid tumors, with a focus on overcoming drug resistance and improving global access to therapies.
History
Viriom has established itself as a significant player in the pharmaceutical industry, particularly in the area of antiviral drug development. The company achieved a milestone by developing Avifavir, the first direct oral antiviral drug, which gained registration in Indonesia. Over the years, Viriom has expanded its drug development pipeline to address various critical diseases, including HIV, Hepatitis B and C, SARS-CoV-2, and influenza. Notably, the company received market authorization for its HIV treatment drug Elpida (elsulfavirine) in Russia and EurAsEC countries, underscoring its commitment to providing innovative treatments across different geographies.
Products
Viriom's product portfolio is diverse and includes several notable treatments. Avifavir, the first approved favipiravir-based drug, is a highlight, particularly for its use in treating COVID-19. Elsulfavirine, marketed as Elpida, addresses HIV with market authorization in Russia and EurAsEC countries. The company is also developing VM3500, a long-acting injectable formulation for HIV-1 infection, and a combination therapy for SARS-CoV-2 infection and COVID-19. Additionally, Viriom has developed AV5124, a targeted therapeutic for treating influenza, which has advanced to human clinical trials, and Quisinostat, a novel selective oral pan-histone deacetylase (HDAC1) inhibitor for ovarian cancer.
Research & Development
Viriom has a strong focus on research and development to address global health challenges. The company launched a Phase II clinical study to evaluate Elsulfavirine for the treatment of COVID-19. It is also developing innovative long-acting oral and injectable formulations for HIV pre- and post-exposure prophylaxis (PrEP and PEP). Viriom's pipeline includes treatments for blood-borne and respiratory viral diseases, as well as solid tumors, highlighting its commitment to advancing treatments for some of the most dangerous viral infections and cancers. The company's dedication to R&D is evident in its ongoing projects, such as developing combination therapies for SARS-CoV-2 and a new influenza therapeutic, AV5124.
Global Partnerships
Viriom actively engages in global partnerships to enhance the reach and impact of its treatments. A significant collaboration includes the licensing agreement signed with P.T. Lloyd Pharma in Indonesia to develop treatments for HIV and Hepatitis B Virus (HBV). This strategic partnership aims to broaden access to essential therapies in both developed and developing countries. By working with international partners, Viriom is able to leverage local expertise and infrastructure, which supports the company's mission to deliver innovative and effective treatments globally.
Sector Focus
Viriom operates in the pharmaceutical sector with a specialized focus on antiviral and oncology treatments. The company concentrates on developing therapies for critical viral diseases, including HIV, Hepatitis B and C, SARS-CoV-2, and influenza. Additionally, Viriom explores treatments for solid tumors, exemplified by their development of Quisinostat for ovarian cancer. This multi-faceted approach enables Viriom to address significant unmet medical needs across a variety of serious health conditions, posing a substantial impact on both patient outcomes and healthcare systems worldwide.